ArticleScientific reports2022
A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- A single polypeptide vaccine derived from multiple antigens confers protection against staphylococcus aureus infection in mice.Tropical diseases, travel medicine and vaccines · 2026Article
- Design of a novel proteome-derived scaffold presenting epitopes of Pseudomonas aeruginosa in native conformation.Scientific reports · 2026Article
- EPY001, a Novel Monoclonal Antibody AgainstInternational journal of molecular sciences · 2025Article
- OmpA virulence factor, a promising conserved vaccine candidate against Acinetobacter baumannii, could trigger autoreactive immune responses in susceptible population.BMC immunology · 2025Article
- Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy againstACS infectious diseases · 2025Article
- Article
- A novel mRNA multi-epitope vaccine of Acinetobacter baumannii based on multi-target protein design in immunoinformatic approach.BMC genomics · 2024Article
- Elesclomol, a copper-transporting therapeutic agent targeting mitochondria: from discovery to its novel applications.Journal of translational medicine · 2023Review
- Recent advances in therapeutic targets identification and development of treatment strategies towards Pseudomonas aeruginosa infections.BMC microbiology · 2023Review
- An Overview of the Impact of Bacterial Infections and the Associated Mortality Predictors in Patients with COVID-19 Admitted to a Tertiary Center from Eastern Europe.Antibiotics (Basel, Switzerland) · 2023Article
- Editorial: Recent advances in the development of vaccines againstFrontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent outbreak of COVID-19 has increased hospital admissions, which could elevate the risk of nosocomial infections, such as A. baumannii and P. aeruginosa infections. Although effective vaccines have been developed against SARS-CoV-2, no approved treatment option is still available against antimicrobial-resistant strains of A. baumannii and P. aeruginosa. In the current study, an all-in-one antigen was designed based on an innovative, state-of-the-art strategy. In this regard, experimentally validated linear epitopes of spike protein (SARS-CoV-2), OmpA (A. baumannii), and OprF (P. aeruginosa) were selected to be harbored by mature OmpA as a scaffold. The selected epitopes were used to replace the loops and turns of the barrel domain in OmpA; OprF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.